Literature DB >> 24567137

Antibody labeling with radioiodine and radiometals.

Suprit Gupta1, Surinder Batra, Maneesh Jain.   

Abstract

Antibodies have been conjugated to radionuclides for various in vitro and in vivo applications. Radiolabeled antibodies have been used in clinics and research for diagnostic applications both in vitro as reagents in bioassays and in vivo as imaging agents. Further, radiolabeled antibodies are used as direct therapeutic agents for cancer radioimmunotherapy or as tracers for studying the pharmacokinetics and biodistribution of therapeutic antibodies. Antibodies are labeled with radiohalogens or radiometals, and the choice of candidate radionuclides for a given application is dictated by their emission range and half-life. The conjugation chemistry for the coupling of MAbs with the radiometals requires a chelator, whereas radiohalogens can be incorporated directly in the antibody backbone. In this chapter, we describe the commonly used methods for radiolabeling and characterizing the antibodies most commonly used radiohalogens (125I/131I) and radiometals (177Lu/99mTc).

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24567137      PMCID: PMC4095879          DOI: 10.1007/978-1-4939-0363-4_9

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  13 in total

Review 1.  Pharmacokinetics and biodistribution of genetically engineered antibodies.

Authors:  Surinder K Batra; Maneesh Jain; Uwe A Wittel; Subhash C Chauhan; David Colcher
Journal:  Curr Opin Biotechnol       Date:  2002-12       Impact factor: 9.740

Review 2.  Antibody-targeted radiation cancer therapy.

Authors:  Diane E Milenic; Erik D Brady; Martin W Brechbiel
Journal:  Nat Rev Drug Discov       Date:  2004-06       Impact factor: 84.694

3.  Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.

Authors:  Marc Hens; Ganesan Vaidyanathan; Xiao-Guang Zhao; Darell D Bigner; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2010-10       Impact factor: 2.408

4.  Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats.

Authors:  M J Abrams; M Juweid; C I tenKate; D A Schwartz; M M Hauser; F E Gaul; A J Fuccello; R H Rubin; H W Strauss; A J Fischman
Journal:  J Nucl Med       Date:  1990-12       Impact factor: 10.057

Review 5.  Engineering antibodies for clinical applications.

Authors:  Maneesh Jain; Neel Kamal; Surinder K Batra
Journal:  Trends Biotechnol       Date:  2007-05-21       Impact factor: 19.536

6.  Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.

Authors:  Marc Hens; Ganesan Vaidyanathan; Phil Welsh; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2009-02       Impact factor: 2.408

Review 7.  Auger electron emitters: insights gained from in vitro experiments.

Authors:  G Makrigiorgos; S J Adelstein; A I Kassis
Journal:  Radiat Environ Biophys       Date:  1990       Impact factor: 1.925

8.  Radiolabeled antibody: iodine versus radiometal chelates.

Authors:  W T Anderson; M Strand
Journal:  NCI Monogr       Date:  1987

9.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

10.  99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma.

Authors:  A Goel; J Baranowska-Kortylewicz; S H Hinrichs; J Wisecarver; G Pavlinkova; S Augustine; D Colcher; B J Booth; S K Batra
Journal:  J Nucl Med       Date:  2001-10       Impact factor: 10.057

View more
  1 in total

1.  Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2-A Candidate for Passive Immunization against COVID-19.

Authors:  Hendris Wongso; Isa Mahendra; Wyanda Arnafia; Idar Idar; Muhammad Yusuf; Arifudin Achmad; Holis A Holik; Ahmad Kurniawan; Iim Halimah; Maula E Sriyani; Teguh H A Wibawa; Muhamad B Febrian; Yanuar Setiadi; Eva M Widyasari; Isti Daruwati; Crhisterra E Kusumaningrum; Toto Subroto
Journal:  Vaccines (Basel)       Date:  2022-01-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.